Inflammasome signalling in brain function and neurodegenerative disease

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• The mammalian central nervous system (CNS) is a complex and vulnerable structure susceptible to damage from injury, pathogens, and neurodegeneration.
• During aging and neurodegenerative diseases, the innate immune system, particularly microglial cells in the brain, can become activated.
• Inflammasomes are intracellular protein complexes that regulate immune responses.

Purpose of the Study:

• To explore the role of inflammasomes, specifically the NLRP3 inflammasome, in microglial cells within the context of CNS injury and neurodegeneration.
• To identify the triggers for inflammasome activation in the brain.
• To understand how inflammasome activation contributes to the development and progression of neurological diseases.

Main Methods:

• The study focuses on the molecular mechanisms of inflammasome activation in brain cells, particularly microglia.
• It involves identifying cellular signals and protein aggregates that trigger inflammasome assembly and activation.
• The research examines the downstream consequences of inflammasome activation, including caspase-1 cleavage.

Main Results:

• Microglia activate the NLRP3 inflammasome in response to various stimuli, including misfolded proteins (amyloid-β, α-synuclein, prion protein) and cellular danger signals (superoxide dismutase, ATP, complement pathway components).
• Other inflammasomes are also present and activated in microglia, astrocytes, and neurons.
• Activation of these inflammasomes leads to caspase-1 cleavage, a key step in inflammatory signaling.

Conclusions:

• Inflammasome activation, particularly NLRP3, in brain-resident immune cells like microglia is a significant factor in neurodegenerative processes.
• The sensing of aggregated proteins and danger signals by inflammasomes drives inflammatory responses implicated in CNS diseases.
• Targeting inflammasome pathways presents a potential therapeutic strategy for neurodegenerative disorders.